![]() | Only 14 pages are availabe for public view |
Abstract Metformin is common oral antidiabetic drug which has been used to treat type II diabetes mellitus (DM) since the mid-fifties of the last century. Although metformin has been for this long period, the exact molecular mechanism of its action is still not fully understood. Tauopathies are group of neurodegenerative diseases (NDDs) characterised by abnormal deposition of filaments made of hyperphosphorylated tau protein. Many risk factors and comorbidities affect the progression of tau pathology including DM and insulin resistance. Due to this correlation, the use of antidiabetic drugs has been proposed as potential therapy for AD. Studies’ results concerning metformin effects on nervous system are conflicting. The present work confirmed the neuroprotective effects of metformin by decreasing the amount of phosphorylated tau protein and reversal of abnormal somatodendritic tau redistribution which are considered as the main pathological hallmarks in all tauopathies. These results could provide new strategies for usage of the commonly used drug (metformin) as an effective therapy for treatment of different tauopathies.. |